Pre-Exposure Prophylaxis (PrEP) Safety and Tolerability in Individuals ≥ 45 Years Old

Abstract

Pre-exposure prophylaxis (PrEP) is a combination of antiretroviral medications, most commonly prescribed as two co-formulated antiretrovirals, taken as a single tablet daily to significantly reduce the risk of human immunodeficiency virus (HIV) infection in individuals at high risk. When taken as prescribed, PrEP is the most effective biomedical intervention to prevent HIV transmission. As such, PrEP is widely acknowledged as a necessary population health tool to combat the HIV epidemic. With upwards of 40,000 new HIV infections occurring in the United States (U.S.) each year and 20% of individuals with HIV in the U.S. unaware of their status, preventing new HIV transmissions through the use of proven interventions such as PrEP is critical [1].